Supernus Pharmaceuticals v. Creekwood: Qelbree® ADHD Patent Dispute Ends in Voluntary Dismissal

Introduction

In a case that resolved faster than most Hatch-Waxman disputes reach their first scheduling conference, Supernus Pharmaceuticals, Inc. v. Creekwood Pharmaceuticals, LLC (Case No. 1:25-cv-00880, D. Del.) closed just 78 days after filing — not with a court ruling, but with a **voluntary dismissal without prejudice**. Filed on July 15, 2025, and closed October 1, 2025, the case centered on six patents protecting Supernus’s branded **Qelbree® viloxazine extended-release capsules**, a non-stimulant ADHD treatment with significant commercial and therapeutic value.

The swift resolution raises strategically important questions for patent attorneys, in-house IP counsel, and pharmaceutical R&D teams: Was this a calculated litigation posture, an out-of-court resolution, or a signal that future enforcement action remains on the table? Because the dismissal was entered **without prejudice**, Supernus retains the right to refile — a detail that carries meaningful implications across the ADHD pharmaceutical space.

Case Overview

The Parties

Patents at Issue

Supernus asserted **six U.S. patents** covering formulation, dosing, and method-of-treatment claims related to viloxazine ER technology, forming a **layered IP portfolio**:

• • US12121523B2
• • US11324753B2
• • US9358204B2
• • US11458143B2
• • US9603853B2
• • US9662338B2

Litigation Timeline & Procedural History

The case was assigned to **Chief Judge Jennifer L. Hall** of the **U.S. District Court for the District of Delaware** — a respected jurist with substantial IP docket experience in one of the nation’s most active patent litigation venues.

The **78-day lifecycle** is exceptionally brief by pharmaceutical patent litigation standards, where cases typically span 18–36 months through claim construction, expert discovery, and trial. The absence of any recorded claim construction hearing, Markman briefing, scheduling order milestones, or motion practice strongly indicates the matter resolved — or was tactically withdrawn — at the earliest procedural stage, before substantive litigation commenced. Delaware’s selection as venue is consistent with Hatch-Waxman practice norms and Supernus’s established history of asserting Qelbree® patents in this district.

The Verdict & Legal Analysis

Outcome

The case closed via a **Notice of Voluntary Dismissal Without Prejudice**, filed by Supernus pursuant to **Federal Rule of Civil Procedure 41(a)**. No damages were awarded. No injunctive relief was granted. No judicial ruling on the merits — validity, infringement, or claim construction — was issued.

The critical legal distinction here is **”without prejudice”**: Supernus expressly preserved its right to refile identical or related claims against Creekwood in the future. This is not a settlement in the traditional sense, nor an abandonment of rights.

Strategic Analysis of the Dismissal

A Rule 41(a) voluntary dismissal at this stage is consistent with several plausible litigation strategies:

• Pre-litigation resolution. The parties may have reached a confidential licensing agreement, consent judgment, or market entry agreement outside the court record.
• Tactical refiling posture. Supernus may have identified procedural, jurisdictional, or evidentiary grounds to refile on stronger footing.
• Demand compliance achieved. Creekwood may have agreed to cease the accused activity, mooting the need for continued litigation.
• Portfolio monitoring action. Brand pharmaceutical companies sometimes file early-stage suits to establish a patent-assertion record and extend the 30-month stay under Hatch-Waxman before strategically dismissing.

Legal Significance

Because no claim construction ruling or validity determination was issued, this case creates **no direct precedent** for the asserted patents’ scope or enforceability. However, the **six-patent portfolio** itself — covering US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — remains fully intact and available for future assertion.

For practitioners tracking viloxazine ER patent litigation, the case signals that Supernus is actively monitoring the competitive landscape and willing to initiate enforcement proceedings swiftly when potential infringement is identified.

Industry & Competitive Implications

The Qelbree® patent portfolio’s active enforcement posture is directly relevant to any pharmaceutical company developing viloxazine-based formulations or non-stimulant ADHD treatments. The ADHD therapeutics market is experiencing significant commercial growth, making Qelbree®’s IP perimeter a high-value enforcement target.

The **without-prejudice dismissal** against Creekwood should not be interpreted by competitors as an enforcement retreat. Supernus has demonstrated both the willingness to litigate and the strategic sophistication to manage its docket efficiently. Companies pursuing ANDA filings or 505(b)(2) applications referencing Qelbree® should anticipate robust patent enforcement responses.

More broadly, this case reflects an industry-wide trend of **early-stage pharmaceutical patent actions** that resolve pre-discovery, often through confidential commercial arrangements that preserve brand manufacturers’ market positions without the cost and uncertainty of full litigation. For in-house IP teams, tracking these short-duration cases is as strategically valuable as monitoring fully litigated outcomes.

Frequently Asked Questions

What patents were involved in Supernus v. Creekwood?

Six U.S. patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — all protecting Qelbree® viloxazine extended-release formulations.

Why was the case dismissed?

Supernus filed a voluntary dismissal without prejudice under FRCP 41(a). No court ruling was issued; the basis for dismissal was not publicly disclosed, suggesting a possible out-of-court resolution.

Can Supernus refile against Creekwood?

Yes. A dismissal without prejudice expressly preserves Supernus’s right to assert the same patents against Creekwood in future proceedings.